Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa
- 17 July 2014
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 371 (3), 234-247
- https://doi.org/10.1056/nejmoa1311274
Abstract
The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain when these agents are used with a protease inhibitor in second-line therapy for human immunodeficiency virus (HIV) infection in resource-limited settings. Removing the NRTIs or replacing them with raltegravir may provide a benefit.Keywords
This publication has 24 references indexed in Scilit:
- High-Levels of Acquired Drug Resistance in Adult Patients Failing First-Line Antiretroviral Therapy in a Rural HIV Treatment Programme in KwaZulu-Natal, South AfricaPLOS ONE, 2013
- Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settingsAIDS, 2012
- Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 studyJournal of Antimicrobial Chemotherapy, 2011
- 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baselineJournal of Antimicrobial Chemotherapy, 2011
- Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical TrialsHIV Research & Clinical Practice, 2010
- Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week AnalysisJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Multiple imputation of discrete and continuous data by fully conditional specificationStatistical Methods in Medical Research, 2007
- The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settingsThe Lancet, 2006
- Multiple imputation of missing blood pressure covariates in survival analysisStatistics in Medicine, 1999
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designBritish Journal of Cancer, 1976